entertainment -WSS

entertainment

author：knowledge 2025-10-02 15:43:27 - browse：229

Blue numbers and letter falling down a tunnel. -- health tech coverage from STAT — Adobe

A growing number of AI tools are being used to predict everything from sepsis to strokes, with the hope of accelerating the delivery of life-saving care. But over time, new research suggests, these predictive models can become a victim of their own success — sending their performance into a nosedive and generating inaccurate, potentially harmful results.

“There is no accounting for this when your models are being tested,” said Akhil Vaid, an instructor of data-driven and digital medicine at the Icahn School of Medicine at Mount Sinai and author of the new research, published Monday in the Annals of Internal Medicine. “You can’t run validation studies, do external validation, run clinical trials — because all they’ll tell you is that the model works. And when it starts to work, that is when the problems will arise.”

Vaid and his Mount Sinai colleagues simulated the deployment of two models that predicted a patient’s risk of dying and acute kidney injury within five days of entering the ICU. Their simulations assumed that the models did what they were supposed to — lower deaths and kidney injury by identifying patients for earlier intervention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Food as medicine: Medically tailored meals may get standardized

explore

WSS

Why the world’s most expensive drug might be worth the price

How one medical school became remarkably diverse

The Readout: Lenmeldy, GLP

Supreme Court strikes down use of affirmative action

Why the world’s most expensive drug might be worth the price

Wildfire smoke exposes gaps in outdoor worker protections

focus

entertainment

explore

As demand for Covid shots wanes, Moderna seeks its next success

At least 13 dead in Texas as scorching temps continue

FDA approval of Sarepta Duchenne genetic therapy gives me hope

There's no autism epidemic. It's an autism diagnosis epidemic

Drug repurposing or repositioning? The language matters

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

BioMarin wins approval for gene therapy to treat hemophilia A

Wildfire smoke exposes gaps in outdoor worker protections

At least 13 dead in Texas as scorching temps continue

The Readout: Lenmeldy, GLP

Wikipedia

Merck drug for rare lung condition set for approval in U.S.

Peter Hotez and the public health issue of online harassment

Activists slam private health insurers over coverage restrictions

Decaf coffee targeted by food safety group under obscure FDA rule

Medical leaders decry Supreme Court decision on affirmative action

Bright Health sells Medicare Advantage business to Molina

hotspot

focus

explore

hotspot